Preclinical studies conducted with T-VEC have demonstrated improved tumor shrinkage and clearance, and clinical studies have shown an enhanced durable response rate for advanced melanoma treatment when compared to use of GM-CSF alone (12, 22). The gene discussed is CSF2; the disease is melanoma.